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Studies showing that neurotrophin binding to p75 NTR can promote cell survival in the absence of Trk (tropomyosin-related kinase)
receptors, together with recent structural data indicating that NGF may bind to p75 NTR in a monovalent manner, raise the possibility that
small molecule p75 NTR ligands that positively regulate survival might be found. A pharmacophore designed to capture selected structural
and physical chemical features of a neurotrophin domain known to interact with p75 NTR was applied to in silico screening of small
molecule libraries. Small, nonpeptide, monomeric compounds were identified that interact with p75 NTR. In cells showing trophic re-
sponses to neurotrophins, the compounds promoted survival signaling through p75 NTR-dependent mechanisms. In cells susceptible to
proneurotrophin-induced death, compounds did not induce apoptosis but inhibited proneurotrophin-mediated death. These studies
identify a unique range of p75 NTR behaviors that can result from isolated receptor liganding and establish several novel therapeutic leads.
Key words: small molecules; nerve growth factor; brain-derived neurotrophic factor; p75; neurotrophin receptor; hippocampal neurons;
oligodendrocytes
Introduction
Neurotrophins [NGF, BDNF, neurotrophin-3 (NT-3), and NT-
4/5] are secreted proteins that have potent effects on neuronal
survival, differentiation, and synaptic function (Chao, 2003;
Huang and Reichardt, 2003; Teng and Hempstead, 2004; Lu
et al., 2005). Mature neurotrophins bind preferentially to
tropomyosin-related kinase (Trk) and p75 NTR, whereas proneu-
rotrophins, which contain an N-terminal domain proteolytically
removed in “mature” forms, interact with p75 NTR and through
their N-terminal domains, with the sorting receptor sortilin
(Fahnestock et al., 2001; Harrington et al., 2004; Nykjaer et al.,
2004). p75 NTR interacts with Trks and modulates Trk signaling
but is also independently coupled to various prosurvival and pro-
apoptotic signaling systems (Salehi et al., 2000; Roux et al., 2001;
Mamidipudi et al., 2002). Depending on the operative ligands,
coexpression of Trk or other receptors, and expression of down-
stream signaling elements, p75 NTR promotes cell survival or
death and modulates neurite outgrowth (DeFreitas et al., 2001;
Chao, 2003). proNGF induces death of superior cervical ganglion
neurons and oligodendrocytes through p75 NTR, and its concom-
itant binding to p75 NTR and sortilin has been shown to activate
death pathways (Lee et al., 2001; Beattie et al., 2002; Nykjaer et al.,
2004). In other systems, p75 NTR signaling through phosphatidyl-
inositol 3-kinase AKT (PI3K/AKT) or interleukin-1 receptor-
associated kinase/nuclear factor B (IRAK/NFB) promotes sur-
vival (Carter et al., 1996; Roux et al., 2001; Mamidipudi et al.,
2002; Reddypalli et al., 2005).
It has been suggested that the unliganded monomeric form of
p75 NTR is proapoptotic and that homodimerization induced by
neurotrophin binding eliminates that effect (J. J. Wang et al.,
2000). This is consistent with studies showing no effects on sur-
vival of monomeric p75 NTR ligands, including monovalent Fabs
(Maliartchouk et al., 2000b) and monomeric cyclic peptides
(Longo et al., 1997), whereas related bivalent forms in each study
promoted cell survival. However, it is unlikely that these mono-
meric ligands engage the receptor in the same way as the natural
ligands. Moreover, although active NGF is a homodimer contain-
ing two potential p75 NTR binding sites, recent structural evidence
suggests it engages only one p75 NTR molecule, disallowing the
binding of another (He and Garcia, 2004). These findings raise
the possibility that small molecules mimicking a single p75 NTR-
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interacting domain of NGF might be found that are capable of
competing with NGF or proNGF binding and/or modifying
p75 NTR signaling and regulating cell survival.
Materials and Methods
Computational modeling, pharmacophore generation, and virtual and
functional screening. Computational studies were performed using the
Accelrys (San Diego, CA) Catalyst and InsightII systems. Three-
dimensional (3D) multiconformer virtual libraries were generated using
catDB and catShape (Accelrys) from molecule files obtained from nu-
merous sources including: The Chapman and Hall/CRC Combined
Chemical Dictionary (Boca Raton, FL), the National Cancer Institute
library of anticancer compounds, and libraries from Maybridge (Corn-
wall, UK), Asinex (Moscow, Russia), Interbioscreen (Moscow, Russia),
Chemstar (Minneapolis, MN), Comgenex (Budapest, Hungary), Timtec
(Newark, DE), and Sigma (rare chemicals dictionary; St. Louis, MO).
Molecular dynamics simulations were performed using the Discover
module within InsightII, using the CFF91 force field and explicit water
solvent. Pharmacophore placement and library searching were per-
formed with Catalyst, as illustrated in Figure 1 and further described in
Results.
Antibodies and proteins. Polyclonal rabbit anti-NGF antibody (Ab) was
obtained from Chemicon (Temecula, CA). Monoclonal anti-phospho-
AKT S473, polyclonal anti-AKT, polyclonal anti-phospho-NFB-
p65 S536, and site-specific polyclonal anti-Trk Y490 (recognizes TrkB Y515)
were purchased from Cell Signaling Technology (Beverly, MA). Mono-
clonal anti-NFB-p65 was obtained from Santa Cruz Biotechnology
(Santa Cruz, CA). Monoclonal anti-actin was purchased from Sigma.
Polyclonal anti-TrkB antibodies were purchased from Upstate (Char-
lottesville, VA). p75 NTR polyclonal rabbit antibodies 9651 (Huber and
Chao, 1995) and 9650 raised against the neurotrophin-binding region
(residues 43–161; cysteine repeat regions II, III, and IV) of the extracel-
lular domain of recombinant p75 NTR were generously provided by Dr.
Moses Chao (Skirball Institute, New York University, New York, NY).
Mouse 2.5 S NGF was purchased from Invitrogen (Carlsbad, CA). Recom-
binant human BDNF was from Sigma. Polyclonal anti-IRAK was obtained
from Santa Cruz Biotechnology, and polyclonal anti-p75NTR antibody was
from Promega (Madison, WI). p75NTR/Fc and TrkA/Fc chimeras were ob-
tained from R & D Systems (Minneapolis, MN). Furin-resistant proNGF
was prepared as described previously (Beattie et al., 2002).
Neuronal bioassays. Hippocampal neurons were prepared from em-
bryonic day 16 (E16) to E17 mouse embryos as described previously
(Yang et al., 2003). Cell survival was examined by microscopic analysis of
morphology and 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium
bromide (MTT) metabolism, or terminal deoxynucleotidyl transferase-
mediated biotinylated UTP nick end labeling (TUNEL) and 4,6-
diamidino-2-phenylindole (DAPI) staining. For morphology/MTT
studies, low-density cultures were initiated in poly-L-lysine-coated A/2
plates by adding 25 l of cell suspension (2000 neurons per well; 12,500
cells/cm 2), 25 l of DMEM containing 10% FBS, and different concen-
trations of recombinant BDNF, NGF, or NGF loop 1 mimic (LM11A)
compounds to each well. After 48 h in culture, cell survival was assessed
as described previously (Longo et al., 1997) using a combination of stan-
dard morphological criteria along with visual determination of whether a
given cell converted MTT to its blue formazan product. The number of
surviving neurons was determined by counting the total number of cells
in each well that were both morphologically intact and filled with blue
product. For each neurotrophin or compound concentration, duplicate
wells were counted and the resulting values averaged. Activity of each
compound was confirmed by blinded counts. Counts were normalized to
survival achieved with 0.95 nM BDNF or to baseline survival. Fitting of
dose–response curves was performed with SigmaPlot (Systat Software,
Richmond, CA).
For TUNEL/DAPI analysis, E16 –E17 mouse hippocampal neurons
were plated on poly-L-lysine-coated cover glasses in 24-well plates (Fisher
Scientific, Pittsburgh, PA) by adding 0.25 ml of cell suspension (20,000
cells/cm 2), 0.25 ml of DMEM containing 10% FBS, recombinant BDNF,
or NGF, and different concentrations of LM11A compounds to each
well. The final concentrations of BDNF and NGF were 1.9 nM. After 48 h
in culture, cell death was assessed using the fluorescein-12-dUTP, Dead-
End Fluorometric TUNEL system (Promega) and Vectashield plus DAPI
(Vector Laboratories Burlingame, CA). Cells were visualized with a flu-
orescence microscope (DM IRE2; Leica, Nussloch, Germany) using 520
nm (TUNEL) and 460 nm (DAPI) filters. For each condition, images of
24 preselected fields (totaling 300 –500 cells) were captured in a nonbi-
ased manner from each of three separate assays. The fraction of dead cells
was determined by dividing the number of nuclei exhibiting TUNEL
staining by the number of DAPI-positive nuclei. Counting was per-
formed in a blinded manner.
For studies using p75 NTR/ and p75 NTR/ neurons, mice carrying a
mutation in exon 3 of the p75 NTR gene (encoding the extracellular do-
main) (Lee et al., 1992) were bred onto a B6 congenic background (10
B6 backcrosses).
For signaling pathway inhibitor studies, 2-(4-morpholinyl)-8-phenyl-
4 H-1-benzopyran-4-one (LY294002), 2-(2-diamino-3-methoxyphenyl-
4 H-1-benzopyran-4-one (PD98059) (Calbiochem, La Jolla, CA), and
SN50 (Alexis, Lausen, Switzerland) were added to cultures at final con-
centrations of 25 M, 50 M, and 2.5 g/ml respectively, concomitantly
with BDNF, NGF, or LM11A compounds. For antibody inhibition stud-
ies, p75 NTR antisera and control nonimmune serum were used at a final
dilution of 1:100 in the presence of BDNF, NGF, or LM11A compounds.
For all studies applying signaling inhibitors, p75 NTR antibodies, or
p75 NTR/ neurons, survival was assessed at 48 h.
Protein extraction and Western blot analysis. For assays of Trk levels and
Trk, AKT, and NFB activation, hippocampal neurons derived from
E16 –E17 mice were cultured in poly-L-lysine-coated six-well plates
(1.5  10 6 cells per well; Corning, Corning, NY) in DMEM containing
10% FBS, followed by incubation in serum-free DMEM for 2 h before
addition of neurotrophins or compounds. At the indicated time points,
neurons were harvested in lysis buffer consisting of: 20 mM Tris, pH 8.0,
137 mM NaCl, 1% Igepal CA-630, 10% glycerol, 1 mM PMSF, 10 g/ml
aprotinin, 1 g/ml leupeptin, and 500 M orthovanadate (Zhou et al.,
1995). Lysates were centrifuged, the supernatant collected, and protein
concentrations determined using the BCA protein assay reagent (Pierce,
Rockford, IL). Western blots were performed as described previously
(Yang et al., 2003). Western blot signals were detected using the ECL
chemiluminescence system (Amersham Biosciences, Arlington Heights,
IL).
NGF and proNGF displacement from p75NTR or TrkA. NGF ELISA was
performed as described previously (Longo et al., 1999). Briefly, 96-well
plates were incubated with 0.1 pmol (at 1 nM) of p75 NTR/Fc or TrkA/Fc
recombinant protein (R & D Systems) overnight at 4°C followed by
incubation with blocking buffer for 1 h at room temperature. proNGF at
1.8 nM or different concentrations of NGF and LM11A compounds were
diluted in sample buffer, added to wells, and incubated for 6 h with
shaking at room temperature. Plates were then washed five times with
Tris-buffered saline (TBS) containing 0.05% Tween 20 and incubated
with anti-NGF rabbit polyclonal antibody overnight at 4°C. After five
washes with TBS, wells were incubated for 2.5 h at room temperature
with anti-rabbit IgG horseradish peroxidase (HRP) conjugate and then
washed five times again. 3,3,5,5-tetramethyl-benzidine substrate was
added and optical density measured at 450 nm. Data showing
compound-mediated displacement of NGF from p75 NTR were fit using
the Nonlinear Regression module of SigmaPlot to the following modifi-




1  10logEC501  C/10logA2	SNGF 
Hill slope  bottom,
where top is the maximal signal, bottom is the basal signal, [C] is
compound concentration, S is the Schild coefficient, Hill slope is the
Hill coefficient, [NGF] is NGF concentration, EC50 is the concentra-
tion of NGF resulting in 50% maximal (top  bottom) binding, and
A2 is the concentration of compound resulting in a doubling of the
EC50 from the curve obtained in the absence of the compound. In these
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studies, the calculated Hill slope ranged from 1.0
to 1.6 and was generally not significantly different
from 1.
p75NTR antibody competition. NIH3T3 fibro-
blasts expressing either null vector or p75 NTR
(Huang et al., 1999) were obtained from Dr.
William Mobley (Stanford University, Stan-
ford, CA). Cells were grown in monolayers,
harvested in PBS with 2 mM EDTA, pelleted,
and resuspended in ice-cold DMEM HEPES
with 1 mg/ml BSA. Six to nine  10 6 cells from
one confluent six-well plate were used for each
experimental point. For binding analysis,
p75 NTR antibody (1:100) was allowed to bind
in the presence or absence of 100 nM LM11A
compounds for 90 min at 4°C with gentle rota-
tion, followed by four washes in PBS. The final
cell pellet was resuspended in lysis buffer.
Western blots were performed as described
above. To detect the presence of p75 NTR anti-
body, blots were probed with horseradish
peroxidase-linked goat anti-rabbit IgG (Amer-
sham Biosciences). Signals were detected by the
ECL chemiluminescence system. To control for
variation in protein loading, the blot was
stripped and reprobed with -actin monoclo-
nal antibody (Sigma).
IRAK-p75NTR coimmunoprecipitation. Pheo-
chromocytoma 12 (PC12) cells (generously
provided by Dr. W. Mobley) (Beattie et al.,
1996) were grown on plates coated with poly-
L-lysine (Sigma) in DMEM containing 5% fetal
calf serum, 100 U/ml penicillin, and 100 g/ml
streptomycin. NGF (1.9 nM) or LM11A com-
pounds (5 nM) were added to the same medium
for 1 min before harvesting. Coimmunopre-
cipitations were conducted as described previ-
ously (Wooten et al., 2001; Mamidipudi et al.,
2002), with 400 g of cell extract incubated
overnight at 4°C with 2 g of polyclonal anti-
p75 NTR antibody followed by 2 h incubation
with 30 l of protein-A beads (Pierce). After
incubation, the beads were washed five times
with protein lysis buffer as described above.
Protein was eluted by boiling for 10 min in 30
l of 2 NuPAGE LDS sample buffer. Aliquots
were submitted to NuPAGE 4 –12% Bis-Tris
Gels (Invitrogen) and transferred to polyvinyli-
dene difluoride membranes. Western blots were
incubated with antibody against IRAK (1:1000)
or p75NTR (1:2000), then with HRP-linked sec-
ondary antibodies. Signal was detected using the
ECL chemiluminescence system.
Oligodendrocyte culture, proneurotrophin
treatment, and cell death assay. Cortical oligo-
dendrocytes from rat pups were prepared as
described previously (Yoon et al., 1998; Harrington et al., 2002). Cells
were treated with recombinant, cleavage-resistant proNGF at 0.05 nM.
Controls were treated with equivalent volumes of proNGF purification
buffer containing 350 mM imidazole. Twenty-four hours after treatment,
cells were fixed and processed for MBP and TUNEL staining as described
previously (Beattie et al., 2002). Two hundred to 250 cells were counted
per well, for a minimum of 600 cells per experimental condition.
Results
Tandem in silico and in vitro screening yields chemically
distinct neurotrophic compounds with high efficiency
Initial modeling of active dimeric cyclic peptides mimicking NGF
-hairpin loop 1, a domain that interacts with p75 NTR (Longo et
al., 2005), suggested that energetic and structural constraints
would disallow simultaneous -hairpin folding of both peptide
subunits, and this implied that the peptides might act in a mono-
meric manner (S. M. Massa, unpublished data). Based on early
virtual screening of 3D conformer libraries, it also seemed un-
likely we would find many functionally dimeric molecules that
were nonpeptides and 
500 Da molecular weight. We therefore
focused on finding compounds emulating a single loop 1 struc-
ture. Compounds were selected for screening in cell survival as-
says by virtual screening of a compound library with a pharma-
cophoric loop 1 model, as outlined in Figure 1. An average of 35
conformers of each of 800,000 compounds were screened,
Figure 1. LM11A compound selection strategy. A, Ribbon representation of the x-ray crystal structure of human NGF with
-turn loops 1, 2, and 4 designated. Average side-chain positions for loop 1 (illustrated), from an ensemble of samples from loop
molecular dynamics simulations, were extracted and used to build a pharmacophoric model. B, Comparison of peptide sequences
of loop 1 from NGF and NT-3 from the indicated species and the assignment of pharmacophores. Guidance for the placement of
pharmacophore features was obtained from consideration of loop phylogeny and side-chain chemistry. As a first approximation,
we assumed that analogous loop 1 peptides from neurotrophins of different species and different neurotrophin family members
should bind similarly to p75 NTR. The primary structure of BDNF loop 1 diverged significantly from NGF and NT-3, and in efforts to
reduce pharmacophore complexity, only the latter two were used. The propensity of histidine to act as a hydrogen bond donor
(McDonald and Thornton, 1994) suggested the use of that feature at position 34, whereas the K-to-R transition at position 32
suggested the use of a positively ionizable feature there. , Positively ionizable group; HBD, hydrogen bond donor; HBA, hydro-
gen bond acceptor. C, Application of the pharmacophoric features to the 3D loop model. Hydrogen bonding features are repre-
sented by pairs of spheres with their relative positions indicating the locations of the acceptor and donor. One of the spheres of the
pair is centered on a putative acceptor/donor feature in the model, whereas the other indicates the target location of a comple-
mentary feature on any potentially interacting molecule. A blue stick bearing a 3D arrowhead extending between the centers of
the spheres also indicates the direction of the bond. Red sphere, Positively ionizable group; purple spheres, hydrogen bond donor
group; green spheres, hydrogen bond acceptor. The diameter of the spheres represents the spatial tolerance for chemical feature
matching in 3D conformer library scans. D, Representative fits to the pharmacophore of two compounds subsequently found to be
active and further investigated in this study.
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yielding 800 compounds with conformers that fit with a calcu-
lated internal energy of 
10 kcal/mol. This number was further
reduced to 60 compounds by visual inspection on the bases of
likely steric compatibility with a hypothetical shallow receptor
binding pocket and maximal flexibility of the functional groups.
Thirty-five compounds were obtained from commercial sources,
of which 23 were soluble in water. In preliminary studies using a
chicken DRG neuronal survival assay, 4 of 23 compounds tested
showed significant neurotrophic activity (Massa et al., 2002,
2003).
Neurotrophic effects of NGF and LM11A compounds are
similar in hippocampal neuron cultures
To extend the evaluation of the compounds from chick DRGs to
mammalian CNS neurons, further biologic analysis of the com-
pounds was performed using embryonic mouse hippocampal
neurons. Under conditions of low density and lack of glial sup-
port, the survival of these neurons is dependent, in part, on the
addition of neurotrophins (Lindholm et al., 1996). Screening of
the 23 previously tested compounds in these cultures demon-
strated activity of three of the compounds (LM11A-7, -24, and
-31) previously identified as having activity in DRG cultures and
identified a fourth active compound, LM11A-28 (structures in
Fig. 2).
To begin to understand the mechanisms of action of these
compounds and test the conjecture that they work via the
targeted receptor p75 NTR we examined the dose–response re-
lationships of the survival-promoting activities of LM11A
compounds compared with NGF and BDNF using embryonic
hippocampal neurons in culture conditions in which NGF
promotes neuronal survival. Similar cultures have been re-
ported to express little or no TrkA (Ip et al., 1993; Marsh et al.,
1993; Brann et al., 1999), but consideration of differences in
species, timing, media, and the presence or absence of a glial
feeder layer prompted examination of Trk expression in the
cultures used in the present studies (Fig. 3A). Western analysis
demonstrated abundant TrkB and no detectable TrkA expres-
sion. Although the expression of TrkA at trace levels cannot be
entirely ruled out, these findings suggest that in these cultures,
neurotrophic activity is mediated by BDNF principally
through TrkB and p75 NTR, whereas NGF functions primarily
through p75 NTR.
Addition of LM11A-7, -24, -28, and -31 increased the num-
ber of GAP-43-positive neurite-bearing cells, consistent with
increased neuronal survival (Fig. 3B, photomicrographs).
Dose–response profiles of the active compounds (Fig. 3C)
demonstrated EC50 values in the range of 100 –300 pM and
intrinsic activities 80 –100% of the NGF response. Maximal
NGF and compound responses were less than that of BDNF.
Although it seems likely this lower level of efficacy was caused
by the simultaneous activation of TrkB and p75 NTR within a
cell by BDNF that does not occur with the other ligands, it
remains possible that it is attributable to differential effects on
neuronal subpopulations expressing different complements of
receptors. Independently synthesized preparations of
LM11A-24 and LM11A-31 gave similar results (data not
shown). LM11A-36, a compound structurally similar to
LM11A-24 (Fig. 2), showed little or no neurotrophic activity.
Using TUNEL/DAPI staining, a similar profile of effects on
preventing cell death were found for BDNF, NGF, and
LM11A-24, -31, and -36 (Fig. 4 A, B), thus confirming the
findings of the morphological/MTT assays. Of note, in both
assays, at compound concentrations 5 nM, survival response
was reduced (Figs. 3C, 4 B). This reduction could have resulted
either from mechanisms unrelated to p75 NTR or from modu-
lation of receptor multimer formation and survival signaling
at higher receptor occupancies, even by a compound without
neurotrophic activity (e.g., LM11A-36). Neurotrophic re-
sponses similar to that of NGF in this hippocampal neuron
system are consistent with activation of survival signaling
through the NGF binding region of p75 NTR.
Of the four active compounds initially identified, two
(LM11A-24, a derivative of caffeine, and LM11A-31, an amino
acid derivative), which were predicted to have “drug-like” char-
acter by Lipinski criteria (Lipinski, 2000) and blood– brain bar-
rier calculations (Clark, 1999; Fu et al., 2001), were chosen for
more detailed mechanistic study. We further prioritized LM11A-
31, because preliminary studies (data not shown) indicated that it
exhibits significant oral uptake and blood– brain barrier penetra-
tion. The relatively inactive compound LM11A-36 was chosen as
a negative control because of its structural similarity to
LM11A-24 (Fig. 2). The hypothesis that the LM11A compounds
work through p75 NTR was examined by investigating the influ-
ence of the compounds on (1) the binding of ligands or antibod-
ies to p75 NTR, (2) neuronal survival with blockade or in the ab-
sence of p75 NTR, (3) maximal cell survival mediated by NGF, and
(4) the activation of signaling systems associated with p75 NTR-
mediated survival. To further explore possible functional differ-
ences between the compounds and neurotrophins, we examined
Figure 2. LM11A compound structures.
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the effects of compounds in oligodendro-
cyte cultures, preparations in which neu-
rotrophins cause, rather than prevent, cell
death.
LM11A compounds interact with
p75 NTR but not TrkA
To assess the interactions of the LM11A
compounds with neurotrophin receptors,
we examined the effects of increasing con-
centrations of compounds on NGF bind-
ing to the recombinant chimeric proteins
p75 NTR-Fc and TrkA-Fc. These chimeric
proteins contain the extracellular regions
of the p75 NTR and TrkA receptors and
thus provide a useful tool for determining
whether compounds affect neurotrophin
binding. LM11A-31 (Fig. 5A) and
LM11A-24 (Fig. 5B), but not LM11A-36
(Fig. 5C), shifted the NGF/p75 NTR-Fc
binding curve significantly to the right.
The inhibition of NGF binding caused by
each active compound was reversed with
increasing NGF concentration, consistent
with a mechanism that is, at least in part,
competitive in nature. When these data
were fit to the Gaddum–Schild equation
that describes ligand binding in the pres-
ence of an inhibitor (Motulsky and Chris-
topoulos, 2003; Neubig et al., 2003) (see
Materials and Methods), the resulting
Schild coefficients were significantly 
1.0
for both active compounds (LM11A-31,
0.58  0.04; LM11A-24, 0.26  0.01), sug-
gesting a more complex model (e.g., mul-
tiple sites within a ligand interacting with a
receptor) (Lutz and Kenakin, 1999; Neu-
big et al., 2003). Gaddum–Schild analysis
also yields a measure of potency that is
independent of the mechanism of inhibi-
tion known as A2 (i.e., the concentration
of compound that shifts the EC50 twofold
to the right). The derivation of the Kd (that
is, the equating of A2 with Kd) for an in-
hibitor in Gaddum–Schild analysis re-
quires a competitive interaction between
the antagonist and the ligand, as indicated
by a Schild coefficient of 1.0. When this is
not the case, A2 nonetheless remains a use-
ful quantitative measure for comparing
compounds within a given system and
provides a basis for comparison with other
parameters such as biologic potency. For
example, LM11A-24 (A2, 31.6  1.3 nM)
and LM11A-31 (A2, 1192  1.2 nM) have
similar biologic potencies (Fig. 3) despite
the 35-fold greater potency of
LM11A-24 in the NGF displacement as-
say; this suggests that properties in addi-
tion to their ability to disrupt NGF binding contribute to the
biological activity of each ligand. It could also suggest different
mechanisms of action between the compounds.
Additional support for the interaction of LM11A-31 with
p75 NTR was obtained through the analysis of LM11A compound
effects on Ab 9651 binding to p75 NTR-expressing fibroblasts. Ab
9651 was raised against the extracellular cysteine-rich repeat re-
gions II, III, and IV, implicated in neurotrophin binding (Huber
Figure 3. LM11A compounds promote hippocampal neuron survival. A, Western blot analysis for TrkA and TrkB expression of
3T3 cells expressing TrkA or TrkB, E16 –E17 mouse hippocampal (Hip) neuronal cultures, and adult hippocampus. TrkA is unde-
tectable in hippocampal cultures and tissues, whereas TrkB expression is readily apparent. B, Representative fluorescence pho-
tomicrographs of E16 –E17 mouse hippocampal neuronal cultures treated with culture medium only (CM) or medium containing
BDNF or LM11A compounds and stained for expression of the neuron-specific, growth-associated protein GAP-43 at 48 h after
treatment. C, Neuron survival dose–response curves of BDNF, NGF, and the LM11A compounds, showing similar potency and
maximal responses, between NGF and LM11A 7, 24, 28, and 31 up to 5 nM, with no response to LM11A-36. BDNF has similar
potency but a higher maximal response. All LM11A compounds showed a decrementing response above 5 nM. Survival was
determined as the total number of cells in each well that were both morphologically intact and filled with blue formazan MTT-
conversion product. Counts were normalized to survival achieved with 0.95 nM BDNF or to baseline survival. n is 4 –18 for all
determinations. The symbols and bars indicate mean  SE, and lines are fits of a single-exponential rise model to the data. The
dotted lines in each graph represent the fitted NGF response.
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and Chao, 1995). Ab 9651 binding to
NIH3T3 cells was dependent on the ex-
pression of p75 NTR (Fig. 5D). In p75 NTR-
expressing cells, coincubation of a high
concentration of LM11A-31 (100 nM)
with antibody, in the absence of NGF, at
4°C (which blocks receptor uptake)
(Schlessinger et al., 1978), caused a signif-
icant decrease in antibody binding,
whereas LM11A-36 (the analog inactive in
binding or functional assays) had no effect
(Fig. 5D). The specificity of LM11A com-
pounds for p75 NTR was supported by ad-
ditional receptor binding studies showing
that the active compounds had no effect
on NGF binding to TrkA (Fig. 5E,F). To-
gether, these results suggest that the com-
pounds interact with the extracellular part
of p75 NTR in a way that can interfere with
the function of the ligand-binding
domain.
LM11A compound activity is
p75 NTR dependent
We then determined whether compound
survival-promoting effects were depen-
dent on the presence of p75 NTR. Ab 9651,
previously shown to block neurotrophic
activity of NGF and NGF loop 1 peptide
mimetics in mouse dorsal root ganglion
neurons (Longo et al., 1997), partially
blocked the neurotrophic activity of
BDNF and NGF (Fig. 6A) and completely
blocked the neurotrophic activity of
LM11A-24 and LM11A-31, whereas non-
immune antibody had no effect. Another
independently derived rabbit polyclonal
anti-p75 NTR antibody (Ab 9650) gave vir-
tually identical results (data not shown),
further corroborating the specificity of
p75 NTR blockade. Neither of the antibod-
ies produced changes in baseline survival
in these cultures. In addition, we exam-
ined the response of p75 NTR / cells to
neurotrophins and the LM11A com-
pounds (Fig. 6B). Baseline survival under
these culture conditions was similar in
p75 NTR/ and p75 NTR/ cells.
p75 NTR/ cultures demonstrated de-
creased responsiveness to BDNF and the
LM11A compounds in a pattern similar to
that found in the p75 NTR antibody studies,
but differed in that the response to NGF
was completely lost. These results are con-
sistent with BDNF acting through both
TrkB and p75 NTR, whereas the LM11A
compounds act primarily through
p75 NTR. The ability of p75 NTR antibody to
completely disrupt activity of LM11A
compounds while only partially disrupt-
ing that of NGF may be a result of differ-
ences between NGF and compounds in
ligand-receptor affinity or steric and/or al-
Figure 4. LM11A compounds inhibit hippocampal culture DNA damage. A, Representative fluorescence photomicrographs of
TUNEL and DAPI staining and merged images of E16 –E17 hippocampal cultures treated with neurotrophins at 1.9 nM or LM11A
compounds at 5 nM. CM, Culture medium only. B, Quantitation of the fraction of DAPI-staining cells that are also TUNEL positive.
Cultures were treated with 1.9 nM neurotrophins or LM11A compounds at the indicated concentrations. n  3 separate assays
(with 100 cells counted per assay) for each condition. Error bars represent mean  SE. *p 
 0.01, **p 
 0.001 by Student’s t
test for comparisons with culture medium only (CM). At 5 nM, LM11A-24 and -31 inhibit TUNEL staining to a degree similar to that
of NGF. At 10 nM, cell-death-preventing activity of compounds is less than that found at 5 nM. LM11A-36 had no detectable effect.
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losteric mechanisms. Finally, treatment
with 5 nM LM11A-24 or -31 along with 1.9
nM NGF, concentrations of each which in-
duce a maximal response, produced no
additive effect on survival (data not
shown), further supporting the hypothesis
that LM11A compounds act through
p75 NTR.
If the LM11A compounds work
through interactions with p75 NTR, we ex-
pect that they should affect its ability to
signal. One of the most proximal NGF-
induced effects on p75 NTR associated with
cell survival is the rapid recruitment to the
receptor of IRAK (Mamidipudi et al.,
2002, 2004). In PC12 cell cultures, addi-
tion of NGF has been shown to induce,
within 1 min, the recruitment of IRAK,
with subsequent downstream activation of
NFB (Mamidipudi et al., 2002). We
found that LM11A-24 and -31, but not
LM11A-36, induced recruitment of IRAK
to p75 NTR in PC12 cells (Fig. 7A).
Despite the observation that
LM11A-24 and LM11A-31 did not affect
NGF-TrkA/Fc binding, it remained possi-
ble that LM11A compounds might acti-
vate TrkB, the principal Trk expressed by
these hippocampal neurons, or the nomi-
nally expressed TrkA, as their primary
mechanism for promoting survival. Also,
ligand binding to p75 NTR might influence
Trk activation. With these considerations,
it was of interest to determine whether
LM11A compounds would promote Trk
activation. LM11A-24 and LM11A-31
were assessed for their ability to activate
Trk autophosphorylation, as indicated by
TrkA Y490 (or the analogous TrkB Y515)
phosphorylation, a well established
marker of Trk activation. In hippocampal
cultures, BDNF exposure resulted in ro-
bust Trk activation (Fig. 7B), whereas no
activation could be detected with NGF or
LM11A compounds. The lack of signal
with NGF confirms that these cultures
produce little or no TrkA and supports the
idea that the trophic effects of NGF are
mediated principally by p75 NTR. In 3T3–
TrkA cells, NGF exposure produced the
expected TrkA autophosphorylation re-
sponse, whereas the LM11A compounds
again showed no activity (Fig. 7C). These
results suggest that activation of Trk re-
ceptors does not play a primary role in promotion of cell survival
by LM11A compounds. In addition, they argue against a mecha-
nism in which the compounds produce their neurotrophic effects
by inducing secretion of endogenous neurotrophins. In particu-
lar, if compounds induced BDNF secretion, we would expect to
detect activation of TrkB in compound-treated hippocampal cul-
tures, which was not observed (Fig. 7B,C). The possibility that
the compounds selectively induce secretion of other factors re-
mains although seems unlikely.
Signaling intermediates activated by LM11A compounds
Prosurvival signaling pathways with well established associations
with p75 NTR actions include activation of NFB (Carter et al.,
1996; Foehr et al., 2000; Gentry et al., 2000; Mamidipudi et al.,
2002; Reddypalli et al., 2005) and PI3K/AKT (Roux et al., 2001;
Lachyankar et al., 2003; Reddypalli et al., 2005). These signaling
intermediates have been shown to be capable of being indepen-
dently regulated by Trk and p75 NTR through pathways with
varying degrees of overlap and cross-talk and with different
Figure 5. LM11A compounds interact with p75 NTR. A, B, NGF/p75 NTR-Fc binding curves, in the presence of increasing concen-
trations (designated in the legend) of LM11A-31 (A) or LM11A-24 (B), as detected by NGF ELISA. Symbols are mean  SE; n  10
for all determinations. The lines represent fitting to a modified Gaddum-Schild equation (see Materials and Methods), with overall
r 2 values of 0.93 for LM11A-31 and 0.96 for LM11A-24. Also, p 
 0.0001 by ANOVA with post hoc Bonferroni/Dunn testing for
comparisons between binding curves at 0 nM compound and curves with 500 nM compound for LM11A-31 and 125 nM for
LM11A-24. Kd for NGF in the absence of compounds was 0.8 – 0.9 nM, consistent with previous reports of 1 nM (Nykjaer et al.,
2004). C, NGF/p75 NTR-Fc binding curves in the presence of increasing concentrations of LM11A-36, showing no significant effect
up to 10,000 nM. Symbols are mean  SE; n  10 for all determinations. D, Representative Western blot showing displacement
of anti-p75 NTR Ab 9651 from p75 NTR-expressing 3T3 cells by LM11A-31, but not LM11A-36. Top, IgG heavy chain; bottom,
-actin; graph, quantitation. Bars represent mean  SE, normalized to bound antibody (lane 4). n  4 for each condition. *p 

0.0005, for comparison with binding in the absence of compound, by Student’s t test. Antibody and compound treatments are
designated above each lane. Ab 9651 did not bind to p75 NTR-negative cells (lanes 1 and 2). Ab 9651 bound to p75 NTR-positive cells
(lane 4) and was significantly displaced by LM11A-31 (lane 5), whereas LM11A-36 had no effect (lane 6). CM, Culture medium only.
E, F, NGF/TrkA-Fc binding curves in the presence of increasing concentrations of LM11A-31 (E) or LM11A-24 (F ), showing no
compound effects up to 10,000 nM. Symbols are mean  SE; n  4 for all determinations.
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kinetics. NFB activation was implicated in the survival-
promoting activities of the LM11A compounds by the finding
that application of an inhibitor of NFB translocation, SN50
(Lin et al., 1995), at a relatively low concentration targeted to
minimize non-NFB interactions (Kolenko et al., 1999) sig-
nificantly reduced cell survival promoted by both LM11A
compounds and the neurotrophins,
with no effect on baseline survival (Fig.
8 A). Trichodion, a compound that in-
hibits NFB activation through the sta-
bilization of IB (Erkel, 2000), gave
nearly identical results (data not
shown). The PI3 kinase inhibitor
LY294002, which inhibits AKT activa-
tion, markedly decreased survival in all
cases, including baseline survival under
conditions of no treatment or exposure
to LM11A-36 (Fig. 8 A). In addition, the
ERK (extracellular signal-regulated ki-
nase) inhibitor PD98059 significantly
decreased BDNF-stimulated survival
and had a small but significant effect on
NGF activity but produced no signifi-
cant decrement in survival promoted by
either LM11A-24 or LM11A-31 (Fig.
8 A). Although these inhibitors are not
completely specific, these studies sug-
gested that ERKs were likely not signifi-
cantly involved in LM11A compound activ-
ity, although the possibility of their action
through the PI3K/AKT and NFB pathways
warranted further characterization.
Consistent with the recruitment of
IRAK to p75 NTR induced by the com-
pounds (Fig. 7A) and the effect of SN50, treatment of hip-
pocampal neurons with 20 nM LM11A-24 or LM11A-31 (a
concentration in the plateau range for acute signaling activa-
tion; see below) led to an 1.5-fold increase in NFB-p65
phosphorylation (Fig. 8 B), indicative of activation of the
NFB pathway (Sakurai et al., 1999), similar in extent and
time course to that induced by both neurotrophin proteins.
LM11A-36 at the same concentration did not induce NFB-
p65 phosphorylation. Examination of compound dose-
activation response (Fig. 8C) demonstrated that LM11A-31
induced activation of NFB over a concentration range of
0.5–3 nM, which is similar to that required for promotion of
survival and concordant with a role for this signaling mecha-
nism in mediating compound-induced survival. In studies of
AKT activation, LM11A-24 and -31 at 20 nM showed similar
degrees of activation to that found with NGF at 30 min,
whereas BDNF induced a substantially greater response. In
addition, the onset of activation stimulated by LM11A-24 and
-31 was slower than that of NGF (Fig. 8 D). Similar to the
observations of NFB, the half-maximal response of AKT ac-
tivation to LM11A-31 was at 1 nM (Fig. 8 E). Finally, we
found that NGF and LM11A compound failed to activate AKT
in cultures of p75 NTR/ neurons (Fig. 8 F). Together with
evidence for the p75 NTR dependence of compound-induced
survival (Fig. 6 A, B), these findings suggest that LM11A com-
pounds induce survival of hippocampal neurons in culture, at
least in part, through interactions with p75 NTR that produce
activation of survival-promoting signaling pathways involv-
ing AKT and NFB. The possibility that LM11A compounds
promote survival by blocking death-promoting activity of en-
dogenous proneurotrophins that might be present in hip-
pocampal cultures is made less likely by the finding that base-
line survival of hippocampal neurons was not affected by the
absence of p75 NTR (Fig. 6 B).
Figure 7. LM11A compounds induce proximal signaling events associated with p75 NTR but
not Trks. A, LM11A compounds induce rapid association of IRAK with p75 NTR. Top, Cell lysates
were immunoprecipitated (IP) with p75 NTR antibody followed by Western blotting (WB) with
either IRAK or p75 NTR antibody as indicated. Bottom, Cell lysate Western blotting, showing no
significant differences in IRAK levels between treatments. Graph, ratios of IRAK coimmunopre-
cipitated with p75 NTR to total p75 NTR. Bars indicate meanSE; n 7 for each condition. *p 

0.05 for comparison with control media, Student’s t test. B, Western blots of hippocampal
neuron cultures using anti-phosphorylated Trk Y490 (which recognizes TrkB Y515) compared with
total TrkB. BDNF activated TrkB, whereas NGF and the LM11A compounds resulted in no detect-
able activation at 10 or 30 min. C, Western blots of TrkA-expressing 3T3 cells using anti-
phosphorylated Trk Y490 compared with total TrkA. NGF activated TrkA, whereas LM11A-31
produced no detectable activation. Results of two additional independent assays for TrkB and
TrkA activation were identical. C, Control media; N, NGF; B, BDNF. 24, 31, and 36 represent the
corresponding LM11A compounds.
Figure 6. LM11A compounds are p75 NTR dependent. A, Ab 9651 has no effect on baseline survival [culture medium only (CM)],
partially inhibits BDNF and NGF, and completely inhibits LM11A-24 and -31 promotion of hippocampal neuron survival. Black bars,
Nonimmune (non-imm) serum treatment; gray bars, Ab 9651 treatment. Bars represent mean  SE; n  11 for each condition.
**p 
 0.0002 (for comparisons between Ab 9651 and nonimmune); NS, not significant by Student’s t test. Survival in the presence
of BDNF or NGF plus Ab 9651 is significantly greater than CM plus Ab 9651 ( p 
 0.000001), whereas the differences between CM
and LM11A compounds in the presence of antibody are not significant. B, p75 NTR deficiency partially inhibits BDNF and completely
inhibits NGF, LM11A-24, and -31 promotion of hippocampal neuron survival. Neurotrophins were applied at 1.9 nM, and com-
pounds were applied at 5 nM. Black bars, p75 NTR/ cells; gray bars, p75 NTR/ cells. Bars represent mean  SE; n  3 for
neurotrophins and n  6 for compounds. **p 
 0.005; NS, not significant (for comparisons between knock-out and wild type) by
Student’s t test. In p75 NTR/ cultures, BDNF treatment produced greater survival than NGF ( p 
 0.05) or any LM11A compound
( p 
 0.01). There was no significant difference in baseline survival between the genotypes.
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LM11A-31 and LM11A-24 do not promote death of mature
oligodendrocytes but inhibit proNGF-mediated death
Although NGF and the LM11A compounds promoted survival in
the hippocampal cultures used in these studies, liganding of
p75 NTR by mature NGF or by proNGF has been associated with
cell death rather than promotion of survival in certain cell types
(Casaccia-Bonnefil et al., 1996; Lee et al., 2001). To determine
whether LM11A compounds would promote survival or cause
death in systems in which neurotrophins promote cell death, we
examined the survival of mature oligodendrocytes treated with
LM11A compounds and proNGF. Mature oligodendrocytes ex-
press p75 NTR but not TrkA and undergo apoptotic death on
treatment with NGF or proNGF (Casaccia-Bonnefil et al., 1996;
Yoon et al., 1998; Beattie et al., 2002). Unlike NGF or proNGF,
LM11A-24, -31, and -36 alone did not promote cell death (Fig.
9A). In addition, proNGF-induced cell death was significantly
inhibited by LM11A-24 and -31 over a concentration range of
1–10 nM, but not by LM11A-36, which appeared to decrease sur-
vival somewhat at 10 nM (Fig. 9A).
To determine whether LM11A compounds block proNGF
binding to p75 NTR, proNGF binding to p75 NTR was assessed over
a concentration range of 1500 –10,000 nM. LM11A-24 and -31
inhibited proNGF binding equally, up to a 30% decrement at
the highest concentration (Fig. 9B).
Discussion
Using knowledge of NGF loop 1 peptide activities (Longo et al.,
1990, 1997), along with available sequence, mutation analysis,
Figure 8. LM11A compounds induce survival signaling similar to, but distinct from, neurotrophins. A, Survival of hippocampal neurons in cultures treated with signaling pathway inhibitors and
BDNF (0.95 nM), NGF (0.95 nM), or LM11A compounds (5 nM), showing substantial inhibition by NFB and PI3K pathway inhibitors, small effects of ERK inhibition on BDNF and NGF activity, and no
effect of ERK inhibition on LM11A compound activity. SN50, An NFB translocation inhibitor; LY, LY294002, a PI3K inhibitor; PD, PD98059, an ERK inhibitor. n  18 for each bar, showing mean 
SE; NS, not significant; *p 
 0.05, **p 
 0.001 for comparison with control (no inhibitor) in each group, Student’s t test. B–F, Western blot analysis of extracts of hippocampal cultures. Top,
Representative bands corresponding to phosphorylated signaling factors (open arrowheads) and the corresponding total factor (filled arrowheads); graphs, quantitation of the ratio of phospho- to
total factor, indicating degree of activation. B, NFB-p65 activation analysis, showing similar activation kinetics for all biologically active treatments. Cells were treated with culture media (C), BDNF
(B) at 1.9 nM, NGF (N) at 1.9 nM, and LM11A compounds at 20 nM. The bars indicate mean  SEM. Black bars, Sampling at 10 min; gray bars, 30 min. n  6 independent blots for each determination.
*p 
 0.05, **p 
 0.005, ***p 
 0.001 for comparison with culture medium only by Student’s t test. C, LM11A-31 dose–response of NFB pathway activation. Bars indicate mean  SE; n  6 for
each condition. p values as indicated, Student’s t test. Activation is detected between 0 and 0.5 nM and reaches a plateau at 5 nM. D, AKT activation analysis as in B, showing a small lag in activation
by the active compounds relative to NGF. E, LM11A-31 dose–response of AKT pathway activation as in C. Activation is detected between 0.5 and 1 nM and reaches a plateau level at 5 nM. F, AKT
activation by growth factors and compounds in p75 NTR/ cells. n  9 for each condition. There are no significant differences between culture medium alone and NGF or the LM11A compounds.
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and x-ray crystallographic structure, we developed a pharma-
cophoric virtual screening method that efficiently identified
[four active of 23 tested compounds (17%)] several chemically
diverse small molecules with potent neurotrophic activity that
interact with p75 NTR. Although attempts to identify nonpeptide
small molecule inhibitors of protein–protein interactions have
recently been fruitful (Berg, 2003), there are relatively few reports
of small molecules, interacting with receptors whose principal
ligands are proteins, that achieve one or more ligand-like effects.
Activators of receptors for thrombopoietin (c-Mpl) (Kimura et
al., 1998), erythropoietin (Goldberg et al., 2002), insulin (Zhang
et al., 1999), and the granulocyte colony stimulating factor (Tian
et al., 1998) were identified by empiric, high throughput screen-
ing. In addition, Maliartchouk et al. (2000a) and Zaccaro et al.
(2005) have developed low-molecular-weight TrkA agonists
through progressive modification of small cyclic peptides emu-
lating a -turn. Virtual (also called in silico) screening of chemical
libraries based on the structure of protein–protein interaction
sites, ligand–receptor interaction sites, or a series of known small
ligands is a potentially powerful approach for the identification of
novel lead compounds (for review, see Kurogi and Guner, 2001;
Mason et al., 2001; Guner, 2002; Singh et al., 2002; Guner et al.,
2004). To date, in the area of modulation of protein–protein
interactions, virtual screening has yielded only inhibitors, includ-
ing compounds inhibiting the interactions of Bak with Bcl-2 (J. L.
Wang et al., 2000), Bak with Bcl-x (Enyedy et al., 2001), major
histocompatibility complex class II proteins with CD4 (Li et al.,
1997), and very late antigen-4 with vascular cell adhesion
molecule-1 (Singh et al., 2002). As in the present work, each of
these screening studies was predicated on identification of an
oligopeptide with the desired function. The results reported here
differ from all previous studies in that we have identified com-
pounds with agonist-like activity. Although binding anywhere
within a pocket may lead to inhibition, it seems likely the struc-
tural requirements for emulating a functional protein ligand–
receptor interaction will generally be more stringent.
Several lines of evidence support the hypothesis that
LM11A compounds work principally through direct interac-
tions with p75 NTR: (1) active compounds fail to elicit prosur-
vival activity and AKT signaling in hippocampal neurons from
p75 NTR/ mice; (2) active compounds appear to interact
with p75 NTR, as demonstrated by their
ability to displace NGF from p75 NTR-Fc
but not from TrkA-Fc; and (3) Ab 9651,
an antibody targeted to the neurotro-
phin binding domain of p75 NTR, inhib-
its compound prosurvival effects and is
displaced from cells by active LM11A
compounds. Additional support for this
contention is provided by the findings
that active compounds induce rapid re-
cruitment of IRAK to p75 NTR, that they
do not activate Trks, and that at maxi-
mum doses, NGF and active compounds
have no additive effects. Thus, p75 NTR
appears to be necessary for LM11A com-
pound activity; however, it remains pos-
sible that the compounds also work in
some measure through low-level or al-
ternative modes of Trk activation, or
through other mechanisms that interact
with p75 NTR. Finally, it was of interest to
note that although they are ostensibly
related only by the property of containing a pharmacophore
designed to mimic the NGF loop 1 p75 NTR binding domain,
the otherwise chemically diverse LM11A compounds have
similar neurotrophic activities and potencies. This observa-
tion is also consistent with the possibility that these com-
pounds act through p75 NTR.
The apparent monomeric nature of these compounds is
consistent with our preliminary computational studies sug-
gesting that peptide dimerization might promote the proper
folding of only one of the peptide subunits. Furthermore,
these findings suggest that cyclic monomeric peptides (Longo
et al., 1997) may be inactive as a result of an inability to main-
tain a proper binding conformation. The subsequent finding
that NGF may be disallowed from simultaneous interaction
with two p75 NTR molecules (He and Garcia, 2004) is consis-
tent with this possibility as well.
The hypothesis that compound activity occurs through
binding to p75 NTR raises the question of whether that mecha-
nism is consistent with the finding that a measure of the
ligand-displacement potency, A2, of LM11A-31 is nearly four
orders of magnitude greater than the EC50 for its biologic
effect (compare Figs. 3C, 5A). We suggest that this finding is
not unexpected, because large differences between biologic
potency of small molecules and apparent binding affinity, as
estimated by ligand displacement, are common (Lutz and
Kenakin, 1999). Potential causes of these differences include:
differences between receptor states in binding versus func-
tional assays; postreceptor signal amplification, such that
maximal biologic effects are seen at low receptor occupancies
(Lutz and Kenakin, 1999); and partial displacement of a mac-
romolecular ligand by a smaller antagonist. In Gaddum–S-
child analysis, a Schild coefficient different from 1.0 suggests a
noncompetitive interaction between the ligand and the antag-
onist; this may occur if the mechanism of antagonism is
through allosteric effects, or if there are multiple ligand bind-
ing sites available on which the antagonist has differential
effects. The latter situation can occur if there are multiple
distinct receptors for the ligand, or, as we propose for the
present case, the ligand binds at several sites on the same
receptor. The current data are consistent with a model in
which the compounds are relatively ineffective in displacing
Figure 9. LM11A-24 and LM11A-31 do not promote death of mature oligodendrocytes and inhibits proNGF-induced death. A,
Mature oligodendrocytes were treated as indicated and cell death assessed by determining the proportion of MBP-positive cells
that are also TUNEL positive. In the absence of proNGF, compounds did not promote cell death. In the presence of 0.05 nM proNGF,
LM11A-24, and LM11A-31, but not LM11A-36, blocked cell death. The bars represent mean  SE; n  2 for each condition except
for 1 nM LM11A-36 with proNGF, which had a single determination. *p 
 0.05, by Student’s t test for comparisons with proNGF
treatment without compounds. B, proNGF displacement from p75 NTR by LM11A-24 and -31. proNGF (1.8 nM) was incubated with
the indicated concentrations of compounds and detected by ELISA. n4 for each condition. The symbols indicate meanSE. The
signals from all compound-treated samples were significantly less than proNGF alone, with p 
 0.01 by Student’s t test.
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NGF from p75 NTR because they interfere at only one of mul-
tiple sites of interaction between the neurotrophin and recep-
tor. This mechanism is also consistent with recently reported
crystallographic structure (He and Garcia, 2004) of a complex
between NGF and p75 NTR, suggesting that there are at least
two interacting patches, with one centered on NGF loop 1. A
purely allosteric model seems less likely (although it is not
ruled out), given the virtually complete reversal of the com-
pound binding at high levels of NGF. The incomplete dis-
placement of NGF by the compounds is similar to that ob-
served in the analysis of small chemokine receptor antagonist
binding (Sabroe et al., 2000).
The high concentrations required to inhibit proNGF bind-
ing compared with those blocking proNGF-induced death of
oligodendrocytes suggest the possibilities that: (1) in the cell-
based assay, with native receptor conformation in the presence
of coreceptors (e.g., sortilin), the proNGF-p75 NTR interaction
may be more susceptible than in the in vitro p75 NTR-Fc assay
to disruption by the compounds; (2) at low concentrations,
the compounds qualitatively alter proNGF binding to de-
crease the induction of cell death but do not decrease the total
amount of proNGF binding; or (3) that the compounds in-
duce preferential activation of prosurvival signaling by
p75 NTR without affecting proNGF binding. Preferential sur-
vival pathway activation by LM11A compounds could result
from differences in the ways the compounds modulate recep-
tor structure, as well as lack of binding to the sortilin corecep-
tor. Indeed, previous studies suggest that engagement of both
sortilin and p75 NTR by proNGF promotes efficient ligand
binding, receptor complex activation, and apoptotic actions
(Nykjaer et al., 2005). Future analyses of signaling in these
cells in response to compounds in the presence or absence of
proNGF may help to further elucidate mechanisms by which
compounds block proNGF-induced oligodendrocyte death.
The potential for differences between activities generated
by a native ligand and small molecule mimetics of a specific
domain of that ligand has important therapeutic implications.
By targeting only one member of a group of receptors that
interact with a given ligand, we may expect to generate com-
pounds that activate a pattern of receptor-mediated effects
that may or may not occur naturally. In the present case, in
targeting p75 NTR, we seem not to activate Trk, but likely acti-
vate pathways involving NFB and PI3K. Such differences in
signaling patterns may eventually prove clinically useful. For
example, the LM11A compounds may promote survival under
conditions in which neurotrophins promote death (as in oli-
godendrocyte death) and may be less likely to induce excessive
sympathetic fiber sprouting and upregulation of pain trans-
mission occurring, likely via Trk signaling, with neurotrophin
treatments (Bergmann et al., 1998; Walsh et al., 1999).
Future systematic studies of these compounds with respect
to the structural details of the binding interface, kinetics of
activation, and pathways involved should enhance our general
understanding of neurotrophin action and promote further
development of specific neurotrophin system modulators for
therapeutic use. Recent evidence suggests that p75 NTR, alone
or interacting with other proteins such as proNGF, might me-
diate cell death in various neuropathological conditions in-
cluding Alzheimer’s disease, spinal cord trauma, axotomy,
and retinal dystrophy (Nykjaer et al., 2005). This raises the
possibility that LM11A compounds will constitute important
leads for therapeutic development. In current studies in our
laboratories, the structural diversity of active LM11A com-
pounds has provided a basis for synthesizing novel com-
pounds designed to incorporate optimal medicinal chemistry
properties.
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